PatientsVille.com Logo

ABNORMAL BEHAVIOUR and Concerta

PatientsVille

ABNORMAL BEHAVIOUR Symptoms and Causes

Alcohol can harm your baby at any stage during a pregnancy. That includes the earliest stages, before you even know you are pregnant. Drinking during pregnancy can cause a group of conditions called fetal alcohol spectrum disorders (FASDs). Children who are born with FASD can have a mix of problems, such as medical, behavioral, educational, and social problems. The kinds of problems they have depend on which type of FASD they have. The problems could include

  • Abnormal facial features, such as a smooth ridge between the nose and upper lip
  • Small head size
  • Shorter-than-average height
  • Low body weight
  • Poor coordination
  • Hyperactive behavior
  • Difficulty with attention and memory
  • Learning disabilities and difficulty in school
  • Speech and language delays
  • Intellectual disability or low IQ
  • Poor reasoning and judgment skills
  • Sleep and sucking problems as a baby
  • Vision or hearing problems
  • Problems with the heart, kidneys, or bones

Fetal alcohol syndrome (FAS) is the most serious type of FASD. People with fetal alcohol syndrome have facial abnormalities, including wide-set and narrow eyes, growth problems and nervous system abnormalities.

Diagnosing FASD can be hard because there is no medical test for it. The health care provider will make a diagnosis by looking at the child's signs and symptoms, and will ask whether the mother drank alcohol during pregnancy.

FASDs last a lifetime. There is no cure for FASDs, but treatments can help. These include medicines to help with some symptoms, medical care for health problems, behavior and education therapy, and parent training. A good treatment plan is specific to the child's problems. It should include close monitoring, follow-ups, and changes when needed.

Certain "protective factors" can help reduce the effects of FASDs and help people who have them reach their full potential. They include

  • Diagnosis before 6 years of age
  • Loving, nurturing, and stable home environment during the school years
  • Absence of violence around them
  • Involvement in special education and social services

There is no known safe amount of alcohol during pregnancy. To prevent FASDs, you should not drink alcohol while you are pregnant, or when you might get pregnant.

Centers for Disease Control and Prevention

Check out the latest treatments for ABNORMAL BEHAVIOUR

ABNORMAL BEHAVIOUR treatment research studies

Concerta clinical trials, surveys and public health registries


Find Drug Side Effect reports



Concerta Side Effects

Aggression (151)
Headache (146)
Suicidal Ideation (145)
Depression (130)
Insomnia (126)
Suicide Attempt (124)
Growth Retardation (119)
Weight Decreased (108)
Tachycardia (106)
Decreased Appetite (102)
Hallucination (94)
Overdose (92)
Chest Pain (91)
Abnormal Behaviour (89)
Psychotic Disorder (85)
Agitation (84)
Anxiety (82)
Nausea (78)
Vomiting (76)
Dizziness (76)
Tic (75)
Hypertension (75)
Convulsion (72)
Product Substitution Issue (71)
Abdominal Pain (65)
Fatigue (63)
Heart Rate Increased (62)
Syncope (57)
Hallucination, Visual (56)
Dyspnoea (55)
Anorexia (54)
Palpitations (53)
Dyskinesia (52)
Intentional Overdose (51)
Arrhythmia (51)
Off Label Use (50)
Disturbance In Attention (49)
Feeling Abnormal (46)
Restlessness (44)
Weight Increased (43)
Tremor (43)
Loss Of Consciousness (42)
Irritability (42)
Psychomotor Hyperactivity (39)
Somnolence (38)
Abdominal Pain Upper (37)
Malaise (37)
Paranoia (36)
Anger (36)
Product Quality Issue (35)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I accedently mixed concerta with asprin and i feel seriously messed up. is it somthing to do with the asprin or is it unrelated? please help

I am just starting my treatment of add with concerta well i have experienced extreme fatigue, sleepinessand mild hallucinations when falling asleep.

I had been taking concerta regularly for seven months up until two weeks ago. I loved the outcome usually and was always very focused while on it, the only negative things were how often my legs fell asleep and the intense mood swings when

I have taken 2 pills, and my metric weight is apoxametly 85 lbs. will i be oaky?

I just started taking Concerta (36 mg) and I immediately developed shingles. My doctor swears it's a coincidence, but after seeing your post I can't help but wonder. I had chicken pox as a child, but I've never had shingles before now. What happened

I took ONE dose-----my head, face and ears itched. My face became all blotchy and swelled up. The skin on my forehead and cheeks started to peel, as if I had a sunburn. $40 I spent to take one pill----which was nothing but POISON. Don't use con

It should be o.k, he's probably experiencing fatigue as a drawback from being off concerta. Concerta can cause imsomnia (the loss of sleep), but given enough time he should recover. If there are more severe symptons he experiences such as pain then g

Last week my son , aged 13, attempted suicide. He had been on concerta for one month.... laughable to see doctors scurry around looking for other reasons as to why this happened . They suggested he stop concerta but of course it's not the fault of th

My 12 yr old son started concerta 6 days ago and he told me today he hears voices , im worried .

My bras constipated from concerta any advice

after taking my medicine .i felt abnormal taste in mouth and my bilurubin level was increased.

After one week on my new medicationfeeling aggressive paranoid and anxious, went from feeling on top of my world to now feeling really 'shitty'This isunusual behaviour for me, I am a professional woman running my own pra

I took centrum for almost one month.and I notice that my menstruation suddenly became abnormal in cycle..in short AMENNORHEA....until now iam almost 1 month and 3 days delayed and took pregnancy test but the result was

<strong>I took 2 capsules at 7.20m after having breakfast and started feeling side effects at 8.25am. It started with increased temperature, abnormal levels of perspiration, dizziness and severe nausea. </strong

1100 sinus rhythm 2210 short pr intrval 9150 abnormal**ecg

9150 **abnormal ecg

Abnormal dreams!!!!

Abnormal ear wax after usage and healing from Ciprodex.

After 2 and half months of taking boniva i devoped severe shoulder pain that cause tendonitis and bursitis and abnormal bone formation and will have to have surgery now to inprove my pain i have been in severe pain for 5 months now boniva side eff

After taking Stilnox I had trouble to control my behaviour, and just as my boyfriend told me I've been walking naked around our neighbourhood ( one out of ton of other things), I realized I must stop taking it. But, since I have such a big trouble sl

ABNORMAL BEHAVIOUR Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting A Study Comparing Long-acting Methylphenidate (ConcertaTM) vs. Placebo in the Treatment of Memory Loss Due to HIV
Condition: HIV Dementia
Interventions: Drug: Long acting methylphenidate;   Drug: Matched placebo
Outcome Measures: Change in rate of reaction time as measured by neuropsychological testing;   Number of Subjects with Adverse Events as Measures of Safety and Tolerability of Concerta in HIV infected adults
2 Recruiting Effects of Methylphenidate (Ritalin®) on the Neural Basis of Anxiety
Condition: PTSD
Interventions: Drug: Methylphenidate;   Drug: Placebo
Outcome Measures: Changes in blood oxygenation level-dependent BOLD signal responses;   Changes in BOLD signal responses;   Changes in skin conductance response;   Latency and accuracy during a interoceptive stimulus task
3 Not yet recruiting The Effect of Ritalin (Methylphenidate Hydrochloride) on Pain and Auditory Sensitivity: an Exploratory Double-blind Randomized Controlled Trial on Healthy Subjects
Condition: Pharmacological Action (PA)
Interventions: Drug: methylphenidate hydrochloride;   Drug: Sugar pill (placebo)
Outcome Measures: Experimental pain intensity measured on a visual analogue scale (0-100);   effect of Ritalin on auditory sensitivity, measured by the response to different auditory stimulations;   pain intensity (NPS 0-100) in response to thermal stimuli and the measures of the auditory tests.
4 Not yet recruiting Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI
Condition: Traumatic Brain Injury
Interventions: Drug: methylphenidate;   Drug: Placebo
Outcome Measures: Relationship between tonic dopamine release (measured by displacement of [11C]-raclopride by oral methylphenidate) and change in processing speed between baseline and after methylphenidate treatment.;   Relationship between D2/D3 receptor availability in ventral striatum and prefrontal cortex and neuropsychologic deficits.;   Relationship between tonic dopamine release in the ventral striatum and prefrontal cortex with neuropsychologic deficits after TBI.;   Relationship between D2/D3 receptor availability and functional connectivity of the prefrontal cortex with nodes of the default mode network.;   Relationship between TMS-induced short-interval cortical inhibition of M1 and tonic dopamine release.;   Test motivation and reward on and off methylphenidate in TBI patients.
5 Recruiting Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study
Conditions: Healthy;   Substance-related Disorder;   Mood Disorder
Interventions: Drug: Methylphenidate;   Drug: Modafinil;   Drug: MDMA;   Drug: Placebo
Outcome Measures: Effect on amygdala and striatum BOLD signal responses to emotional stimuli;   Effects on cognitive performance and associated BOLD signal changes in frontal areas;   Subjective effects;   Neuroendocrine effects;   Empathy and social behavior;   Physiological effects of methylphenidate, modafinil, and MDMA;   Genetic Polymorphisms;   Pharmacokinetics of methylphenidate, modafinil, and MDMA
6 Recruiting Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders
Conditions: Attention Deficit/Hyperactivity Disorder;   Oppositional Defiant Disorder;   Conduct Disorder
Interventions: Drug: Methylphenidate;   Drug: Risperidone
Outcome Measures: Change from baseline of aggressive behaviors.;   Clinical Global Impression - Improvement scale (CGI-I) questionnaire;   ADHD-RS questionnaire;   Children's Depression Rating Scale (CDRS) questionnaire;   Young Mania Rating Scale (YMRS) questionnaire;   Children Sleep Habits Questionnaire (CSHQ);   Clinical Global Impression - Severity (CGI-S) questionnaire
7 Unknown  Study of Methylphenidate as Add on Therapy in Depressed Cancer Patients
Condition: Depression
Interventions: Drug: Methylphenidate;   Drug: Placebo
Outcome Measures: depressive symptoms;   Distress level
8 Recruiting Methylphenidate for Attention Problems After Pediatric TBI
Conditions: Traumatic Brain Injury;   TBI;   ADHD
Interventions: Drug: Methylphenidate;   Drug: Placebo
Outcome Measures: Parent report measures;   Neuropsychological Testing;   Teacher Report Measures
9 Recruiting Methylphenidate to Improve Balance and Walking in MS
Condition: Multiple Sclerosis
Interventions: Drug: Methylphenidate (Ritalin);   Drug: Placebo
Outcome Measures: Timed Up and Go time (TUG time);   Automatic Postural Response (APR) Latency (in sec);   Timed 25 Foot Walk (T25FW in secs);   Pittsburgh Sleep Quality Assessment Questionnaire score;   Modified Fatigue Index Scale score;   Vestibular-Ocular Reflex time (in secs)
10 Not yet recruiting Methylphenidate on Intracortical Inhibition in Methamphetamine Abusers Attention Deficit Hyperactivity Disorder (ADHD)
Condition: Attention Deficit Hyperactivity Disorder
Intervention: Other: methylphenidate tablets and Inter-stimulus Intervals (ISI)
Outcome Measures: Conners ADHD Rating Scale;   Change of Motor Evoked Potential (MEP)
11 Recruiting Methylphenidate as Treatment Option of Fatigue in Multiple Sclerosis
Conditions: Multiple Sclerosis;   Fatigue
Interventions: Drug: Methylphenidate modified release;   Drug: Maltodextrin
Outcome Measures: Change of Fatigue as measured by Fatigue Severity Scale;   Change of Fatigue as measured by Modified Fatigue Impact Scale (MFIS)
12 Recruiting Multimodal Therapy for Treatment of Fatigue
Condition: Prostate Cancer
Interventions: Other: Placebo;   Drug: Methylphenidate;   Behavioral: Counseling Sessions;   Other: Sham Exercise;   Other: Standardized Exercise Intervention Program;   Other: Cognitive Behavioral Therapy (CBT)
Outcome Measure: Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) subscale scores
13 Recruiting Control of Cognition
Conditions: Healthy;   Attention Deficit Hyperactivity Disorder;   Alcohol Dependence;   Attention Deficit Hyperactivity Disorder and Alcohol Dependence
Interventions: Drug: Methylphendiate;   Drug: Naltrexone;   Drug: Placebo
Outcome Measures: Identify abnormalities in prefrontal control neural circuits underlying attention control, motor control, and appetitive control;   Characterize effects of methylphenidate and naltrexone on neural circuits in prefrontal cortex associated with attention control, motor control, and appetitive control;   Reaction time on the Multi-Source Interference Task;   Accuracy on the Multi-Source Interference Task;   Reaction time variability on the Multi-Source Interference Task
14 Recruiting The Effect of Methylphenidate Treatment in Familial Attention Deficit/Hyperactivity Disorder (ADHD)
Conditions: Attention Deficit/Hyperactivity Disorder Combined Type;   ADHD Predominantly Inattentive Type;   ADHD Predominantly Hyperactivity Type;   ADHD-not Other Specified
Intervention: Drug: Methylphenidate- Ritalin IR (Immediate Release)
Outcome Measures: Clinical Global Impression-Improvement scale;   overall ADHD-Rating Scale (ADHD-RS) score
15 Unknown  Amantadine Versus Ritalin in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: Amantadine;   Drug: ritalin
Outcome Measure: The mean decrease in ADHD -RS-IV score from baseline will be used as the main outcome measure of response of ADHD treatment.
16 Not yet recruiting Identifying Characteristic Signature of Attention Deficit / Hyperactivity Disorder (ADHD) and Ritalin Treatment
Condition: "Attention Deficit Hyperactivity Disorder"
Interventions: Drug: Ritalin;   Drug: Placebo
Outcome Measure: Resting oscillation activity and Event-related-Potentials in Attention Deficit / Hyperactivity Disorder (ADHD) and healthy subjects.
17 Not yet recruiting Reversal of General Anesthesia With Methylphenidate
Conditions: Post Operative Cognitive Dysfunction;   Emergence From Anesthesia
Intervention: Drug: Methylphenidate
Outcome Measures: Number of Participants with Adverse Events as a Measure of Safety and Tolerability;   Time to emergence from general anesthesia
18 Recruiting A Comparison of Methylphenidate and Cognitive Behavioural Therapy for the Treatment of Binge Eating Disorder
Condition: Binge-Eating Disorder
Interventions: Drug: Methylphenidate;   Behavioral: Cognitive Behavioral Therapy
Outcome Measures: Frequency of binge episodes/days, as assessed by prospective daily binge diary;   Frequency of objective binge episodes and overall illness severity, as assessed by both the Eating Disorder Examination Interview and Questionnaire;   Clinician impression of illness severity and improvement, as assessed by the Clinical Global Impression scale;   Quality of life, as assessed by the Quality of Life Inventory;   Associated features of binge eating as captured by the Dutch Eating Behavior Questionnaire and Binge Eating Scale;   Body Mass Index
19 Recruiting Impact of CES1 Genotype on Metabolism of Methylphenidate
Conditions: Carboxylesterase 1 (CES1) Genotype;   CES1 Activity
Intervention: Drug: Methylphenidate
Outcome Measures: Plasma concentration of methylphenidate and ritalinic acid;   Metabolomic Profile
20 Not yet recruiting Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
Conditions: Attention-deficit/Hyperactivity Disorder;   Autism Spectrum Disorder
Intervention: Drug: Methylphenidate extended-release liquid formulation
Outcome Measure: Adult ADHD Investigator Symptom Report Scale (AISRS)